The antibody according to any one of claims 1-8, wherein said antibody comprises at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein said heavy chain variable region is a heavy chain variable region of an antibody selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_l, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and/or M25wtLF
The total tirzepatide is the same, but the volume and the number of units per dose are completely different
[DOI] [PMC free article] [PubMed] [Google Scholar] 264.Qi Y., Zhang H., Liang S., Chen J., Yan X., Duan Z., Zhou D., Li Z
A NATIONWIDE ANALYSIS Shahryar Khan 1 Yousaf Zafar 2 Amina Arif 3 Muhammad Abu Bakkar 4 Azzah Muhammad Hayat 4 Mashal Alam Khan 4 , 1 University of Kansas Medical Center, 2 University of Mississippi Medical Center, 3 University of Nevada, Reno School of Medicine, 4 Khyber Medical University Background: Hepatorenal syndrome (HRS) is a serious complication of Advanced Liver Disease with high rates of morbidity and mortality
